JP Morgan Chase
PMCB icon

JP Morgan Chase’s PharmaCyte Biotech PMCB Stock Holding History

JP Morgan Chase’s Portfolio PMCB Stock Details PMCB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-16
Closed -$20 – 7510
2025
Q1 		$20 Sell
16
-2
-11% -$3 ﹤0.01% 7125
2024
Q4 		$28 Hold
18
– – ﹤0.01% 7230
2024
Q3 		$34 Sell
18
-1
-5% -$2 ﹤0.01% 7175
2024
Q2 		$37 Buy
19
+1
+6% +$2 ﹤0.01% 7077
2024
Q1 		$43 Buy
18
+6
+50% +$13 ﹤0.01% 7068
2023
Q4 		$26 Sell
12
-5
-29% -$11 ﹤0.01% 7304
2023
Q3 		$36 Buy
+17
New +$43 ﹤0.01% 7053
2022
Q2 		– Sell
-2,723
Closed -$6K – 6784
2022
Q1 		$6K Buy
+2,723
New +$6.05K ﹤0.01% 6295

Other funds holding PMCB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EPM
Equitec Proprietary Markets Chicago, Illinois $559M AUM 230.29% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
National Bank of Canada
National Bank of Canada Montreal, Quebec, Canada $140B AUM 46.34% 1-Year Est. Return

JP Morgan Chase's PMCB Position: Q2 2025 in Review

JP Morgan Chase sold out of PharmaCyte Biotech (PMCB) in Q2 2025, closing a stake of 16 shares — an estimated $20 sold.

JP Morgan Chase first reported a position in PMCB in Q1 2022 and held it in 8 quarters. The position peaked at $6K in Q1 2022. 23 funds tracked by Wall St. Rank hold PMCB as of Q2 2025.

  • JP Morgan Chase reported no remaining PharmaCyte Biotech position as of Q2 2025 after selling out during the quarter.
  • JP Morgan Chase sold 16 PharmaCyte Biotech shares in Q2 2025, an estimated $20.
  • JP Morgan Chase first reported a position in PharmaCyte Biotech in Q1 2022 and held it in 8 quarters.
  • JP Morgan Chase's PharmaCyte Biotech position peaked at $6K in Q1 2022.
  • 23 funds tracked by Wall St. Rank held PharmaCyte Biotech as of Q2 2025.

Based on JP Morgan Chase's 13F filing for Q2 2025, filed 12 Aug 2025.